Immunomodulatory properties of characellide A on human peripheral blood mononuclear cells.
Simone MarcellaSam AfoulloussOlivier P ThomasA Louise AllcockPaul V MurphyStefania LoffredoPublished in: Inflammopharmacology (2021)
Marine sponges and their associated microbiota are multicellular animals known to produce metabolites with interesting pharmacological properties playing a pivotal role against a plethora of pathologic disorders such as inflammation, cancer and infections. Characellide A and B belong to a novel class of glycolipopeptides isolated from the deep sea marine sponge Characella pachastrelloides. In this study, we have evaluated the effects of characellide A and B on cytokine and chemokine release from human peripheral blood mononuclear cells (PBMC). Characellide A induces a concentration- and time-dependent CXCL8, IL-6 and TNF-α release from PBMC. This production is mediated by the induction of gene transcription. Moreover, cytokine/chemokine release induced by characellide A from PBMC is CD1d-dependent because a CD1d antagonist, 1,2-bis(diphenylphosphino)ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically inhibits characellide A-induced activation of PBMC. In conclusion, characellide A is a novel modulator of adaptative/innate immune responses. Further studies are needed to understand its potential pharmacological application.
Keyphrases
- immune response
- endothelial cells
- high glucose
- induced pluripotent stem cells
- rheumatoid arthritis
- pluripotent stem cells
- neoadjuvant chemotherapy
- papillary thyroid
- ms ms
- toll like receptor
- dna methylation
- drug delivery
- squamous cell carcinoma
- ionic liquid
- dendritic cells
- radiation therapy
- lymph node
- inflammatory response
- case control